Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05608252 · ClinicalTrials.gov registry record · Phase 1
VS-6766+Abema+Fulv in Met HR+/HER- BC
A Phase 1 study of Breast Cancer and Hormone Receptor-Positive Breast Cancer, sponsored by Adrienne G. Waks.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 3
- Study locations
NCT05608252 is a Phase 1 study of Breast Cancer and Hormone Receptor-Positive Breast Cancer that is actively recruiting participants, run by Adrienne G. Waks. The registered enrollment target is 63 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT05608252, a Phase 1 study of Breast Cancer and Hormone Receptor-Positive Breast Cancer, is actively recruiting participants, sponsored by Adrienne G. Waks.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: * VS-6766 * Abemaciclib * Fulvestrant
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG VS-6766
- DRUG Abemaciclib
Study Locations (3)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institite - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2023-02-23 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05608252
The ClinicalTrials.gov registry entry for NCT05608252 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Adrienne G. Waks, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Fulvestrant is the first listed.
NCT05608252 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05608252 about?
NCT05608252 is a clinical study titled "VS-6766+Abema+Fulv in Met HR+/HER- BC". This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: * VS-6766 * Abemaciclib * Fulvestrant
What is the current status of trial NCT05608252?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2023-02-23. Estimated completion is 2028-12-31.
What conditions does trial NCT05608252 study?
This clinical trial studies the following conditions: Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer.
What interventions are being tested in trial NCT05608252?
The interventions under investigation include: Fulvestrant (DRUG), VS-6766 (DRUG), Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT05608252?
This trial is sponsored by Adrienne G. Waks, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05608252 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Breast Cancer
All registered trials for this condition
Hormone Receptor-Positive Breast Cancer
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.